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Background: The efficacy of chemotherapy regimens in breast cancer patients is variable and unpredictable.
Whether individual patients either achieve long-term remission or suffer recurrence after therapy may be dictated
by intrinsic properties of their breast tumors including genetic lesions and consequent aberrant transcriptional
programs. Global gene expression profiling provides a powerful tool to identify such tumor-intrinsic transcriptional
programs, whose analyses provide insight into the underlying biology of individual patient tumors. For example,
multi-gene expression signatures have been identified that can predict the likelihood of disease reccurrence, and
thus guide patient prognosis. Whereas such prognostic signatures are being introduced in the clinical setting,
similar signatures that predict sensitivity or resistance to chemotherapy are not currently clinically available.
Methods: We used gene expression profiling to identify genes that were co-expressed with genes whose
transcripts encode the protein targets of commonly used chemotherapeutic agents.
Results: Here, we present target based expression indices that predict breast tumor response to anthracycline and
taxane based chemotherapy. Indeed, these signatures were independently predictive of chemotherapy response
after adjusting for standard clinic-pathological variables such as age, grade, and estrogen receptor status in a cohort
of 488 breast cancer patients treated with adriamycin and taxotere/taxol.
Conclusions: Importantly, our findings suggest the practicality of developing target based indices that predict
response to therapeutics, as well as highlight the possibility of using gene signatures to guide the use of
chemotherapy during treatment of breast cancer patients.
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Oncologists are faced with the challenging task of select-
ing the most effective therapies for individual cancer
patients to achieve the best possible outcome. Indeed,
the latter is the central goal of personalized cancer medi-
cine. Trastuzumab is one of the best examples illustrat-
ing the importance of tailoring treatment to the
characteristics of an individual’s tumor. In the absence
of patient selection only 10% of breast cancer patients* Correspondence: hassell@mcmaster.ca
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reproduction in any medium, provided the orderive clinical benefit from trastuzumab treatment [1].
However, when patients are selected for trastuzumab
therapy based on ERBB2/HER2 gene amplification, their
response rate rises to as high as 50%. The development
of global gene expression profiling technologies, such as
DNA microarrays, has provided additional avenues to
identify the molecular features of tumors that are asso-
ciated with clinical variables, such as tumor grade or
outcome. In fact, sets of genes, commonly called gene
signatures, have been identified that predict patient
prognosis, and are already used in various clinical set-
tings [2-8].
Many current studies focus on identifying similar gene
signatures to guide the selection of appropriate chemo-
therapy regimens [9-12]. However, gene signatures thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are not currently clinically available. The development
and clinical implementation of gene signatures that pre-
dict response to commonly used chemotherapeutic
agents could facilitate selecting the most efficacious thera-
peutic regimen given the molecular characteristics of
an individual’s tumor. Furthermore, therapy-predictive
gene signatures could ensure patients do not receive in-
effective and potentially deleterious chemotherapeutic
regimens.
Measuring the inherent chemosensitivity of a tumor
can be accomplished by assessment of pathological re-
sponse following neoadjuvant treatment with a given
treatment regimen. In this fashion, patients in which no
invasive or metastatic breast cancer can be detected fol-
lowing treatment are classified as having achieved
complete pathological response (pCR), whereas patients
that fail to achieve pCR are classified as having residual
disease (RD). Importantly, neoadjuvant chemotherapy
has been found to be as efficacious as chemotherapy
given in the adjuvant setting, and patients who achieve
complete pathological response after neoadjuvant inter-
vention generally have an excellent probability of experi-
encing long-term survival [13-15]. Taken together, these
data suggest that response to neoadjuvant chemotherapy
(pCR/RD) provides a relevant clinical model to develop
and validate gene signature based predictors of breast
tumor response to chemotherapy.
We sought to test whether TOP2A and β-tubulin
transcript expression indices could predict response to
commonly used chemotherapeutic agents, as the pro-
tein products of these genes represent the respective
molecular targets of commonly used anthracycline- and
taxane-related drugs [16-18]. We hypothesized that
such target based expression indices would provide a
biologically comprehensive measurement of either TOP2A
or β-tubulin activity in a patient’s tumor, and thus its likely
dependence on either of these targets. Importantly, these
analyses establish an effective method for identifying pre-
dictive drug response signatures, and highlight the use of
predictive gene signatures to guide the selection of anthra-
cycline and taxane based chemotherapy regimens for breast
cancer patients.
Results
TOP2A and β-tubulin expression are associated with
complete pathological response in breast cancer patients
treated with chemotherapy
As proof-of-principle that target expression could be
linked to chemotherapy response, we tested whether
transcripts of TOP2A were associated with pCR in a
relatively large (GSE21094, n = 278, n = 56 pCR, n = 222
RD) cohort of breast cancer patients treated with a
neoadjuvant chemotherapy regimen that contained ananthracycline (TFAC; paclitaxel [T], 5-FU [F], adriamy-
cin [A] and cyclophosphamide[C]). TOP2A transcript
levels were associated with increased response to
chemotherapy (Figure 1A, AUC: 0.61, p= 0.008), and the
mean expression of TOP2A transcripts was higher in
patients who showed a complete pathological response
than those who displayed residual disease after treat-
ment (Figure 1B, RD: 122.5, pCR: 167.7, p= 0.04, t-test,
Welch’s correction). Importantly, these data suggested
that elevated expression levels of TOP2A transcripts are
associated with response to anthracycline based chemo-
therapy regimens, and are consistent with previous stud-
ies that link TOP2A expression with response to
anthracycline therapy [19-21]. To extend these findings,
we also tested whether β-tubulin expression was asso-
ciated with pCR in a cohort of breast cancer patients trea-
ted with docetaxel. β-tubulin transcript levels were linked
with increased response to docetaxel (Figure 1C, AUC:
0.9, p=0.001), and the mean expression of β-tubulin tran-
scripts was higher in complete responders than those
whose tumors did not achieve a complete response
(Figure 1D, RD: 2344, pCR: 1364, p< 0.0001, t-test). In-
deed, these findings are consistent with previous studies
that link β-tubulin expression with sensitivity to taxane
chemotherapy [22]. In total, these experiments suggest
that target expression is associated with response to their
chemotherapeutic agent counterparts.
The TOP2A index is associated with complete
pathological response in breast cancer patients treated
with anthracyclines
Our previous observations suggested the expression of
transcripts encoding the protein targets of therapeutic
agents was associated with response to these same ther-
apies. To extend these findings, we calculated a TOP2A
transcript expression index by identifying genes whose
expression displayed either positive or negative correl-
ation to the expression of TOP2A transcripts in 3 inde-
pendent publicly available data sets (GSE2034, GSE7390,
GSE6532) (Figure 2A). In short, we measured the correl-
ation of all probe sets to TOP2A expression and selected
those that ranked among the top and bottom 1% of all
probe sets in each data set. The latter approach identi-
fied 124 TOP2A associated probe sets, 86 that displayed
positive association to TOP2A transcripts and 34 that
were negatively associated with TOP2A transcripts
(Figure 2B, Additional file 1: Table S1). Using the same
278 patient cohort we employed previously, the TOP2A
index was significantly associated with pCR (Figure 2D,
AUC: 0.73, p < 0.0001) and the TOP2A index scores
were higher in patients who demonstrated a pCR than
those who retained RD after treatment (Figure 2E, RD:–
0.15, pCR: 0.60, p < 0.0001, t-test,). Notably, the TOP2A
index included genes linked to DNA repair, including
Figure 1 TOP2A and β-tubulin transcript levels predict response to anthracycline or taxane containing chemotherapy, respectively. A)
ROC analysis of TOP2A transcript levels and response to TFAC neoadjuvant chemotherapy (AUC: 0.61, p= 0.008). B) Expression levels of TOP2A
transcripts in patients who experienced pCR or had RD after neoadjuvant chemotherapy (p= 0.04, t-test). C) ROC analysis of β-tubulin transcript
levels and response to neoadjuvant docetaxel chemotherapy (AUC: 0.9, p= 0.001). D) Expression levels of β-tubulin transcripts in patients who
experienced pCR or had RD after neoadjuvant docetaxel chemotherapy (p< 0.0001, t-test).
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that the TOP2A index has a functional connection to
the mechanisms of action of anthracycline drugs. To
look for similarities between the TOP2A index and other
predictors of chemotherapy response, we examined
whether TOP2A index probes were also present within
the DLDA30 predictor. Importantly, the DLDA30 is a
validated gene expression based predictor of response to
taxanes and anthracyclines, as well as to 5-fluorouracil
and cyclophosphamide [9,10,12]. Interestingly, only one
probe set from the TOP2A index also comprised an
element in the DLDA30 predictor, suggesting minimal
overlap between these two gene expression based predic-
tors. Taken together, these data provide proof-of-
principle that a target based expression index can pre-
dict response to small molecules that inhibit the activity
of the given target under investigation. Importantly, we
show here that the TOP2A index was associated with
complete pathological response in breast cancer patients
treated with an anthracycline containing chemotherapy
regimen in the neoadjuvant setting. A β-tubulin index is
associated with complete pathological response in breast
cancer patients treated with taxanes Given the develop-
ment of the TOP2A index, we explored the possibility of
identifying and developing a similar index to predictresponse to taxane drugs (Figure 3A). In a similar fash-
ion as reported above, we identified an expression index
of β-tubulin associated transcripts. β-tubulin is the mo-
lecular target of taxane drugs, a commonly used class of
chemotherapeutic drugs that includes docetaxel and
paclitaxel (TaxotereW and TaxolW respectively)[27-29]. In
short, we identified 42 β-tubulin transcript-associated
probe sets, 28 that displayed positive association with
β-tubulin transcripts and 14 that were negatively asso-
ciated with β-tubulin transcript levels (Figure 3B). We
evaluated the association between the β-tubulin index
and response to docetaxel using a 14 patient (profiled
in replicate, n = 28, RD: 20, pCR: 8) cohort that was
treated with neoadjuvant docetaxel (Figure 3C). The
β-tubulin index was associated with complete patho-
logical response (Figure 3D, AUC: 0.89, p = 0.002) and
β-tubulin index scores were higher in patients who
achieved complete pathological response than those
who experienced residual disease after docetaxel ther-
apy (Figure 3E, RD: -0.5, pCR: 1.3, p < 0.0001, t-test).
Interestingly, the β-tubulin index included genes linked
to cytoskeleton processes, including TPX2[30], and DBN1
[31], suggesting a linkage between the β-tubulin index and
the mechanism of action of taxanes. As completed previ-
























TOP2A signature related to
neoadjuvant response?
C D E
Figure 2 TOP2A index predicts response to anthracycline containing chemotherapy. A) Experimental strategy to identify the TOP2A index.
B) TOP2A co-expressed probesets within the three discovery cohorts. C) Experimental strategy to validate the TOP2A index. D) ROC Analysis of
TOP2A index scores and response to T/FAC neoadjuvant chemotherapy (AUC: 0.73, p< 0.0001). E) TOP2A index scores of patients who
experienced pCR or had RD after neoadjuvant chemotherapy (p< 0.0001, t-test).
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probe sets from the β-tubulin index comprised an element
within the DLDA30 predictor, suggesting minimal overlap
between these two gene expression based predictors. In
total, these data provide evidence that target based expres-
sion indices can predict response to neoadjuvant chemo-
therapy. In each case, the area under curve (AUC) was
significantly greater than 0.5, confirming the predictive cap-
acity of the indices, as well as the overall validity of the
approach.
Combining indices is predictive of response to multi-
agent chemotherapy
Neoadjuvant chemotherapy generally comprises multiple
different chemotherapeutic agents. To determine whether
we could combine our individual target indices and pre-
dict response to multi- agent chemotherapy we tested the
TOP2A and β-tubulin indices as a combination index with
the 278–patient cohort (TFAC), as well as with two differ-
ent cohorts of patients treated with neoadjuvant therapy
comprising an anthracycline and a taxane (AT) (GSE25055
[n=310] & GSE25065 [n=198]). The individual TOP2A
and β-tubulin indices were associated with response amongthe TFAC-treated patients, and patients who experienced
pCR had significantly higher individual index scores than
those who retained residual disease (Figure 4A, p<0.0001
both cases, t-test). After combining the indices for the 278
TFAC-treated patient cohort, we observed a significant as-
sociation between the combined indices and tumor
response (Figure 4B, AUC: 0.76, p<0.0001), and the com-
bined index scores were significantly higher in responders
(pCR) than non-responders (RD) (Figure 4C, RD:–0.4,
pCR: 1.7, p<0.0001, t-test). Interestingly, the AUC value for
the combined TOP2A and β-tublin index was nominally
higher (AUC: 0.78) than that produced by the TOP2A
index alone (Figure 2D, AUC:0.73). We also tested the
TOP2A and β-tubulin combination index on an additional
two independent cohorts of patients treated with AT neoad-
juvant chemotherapy (GSE25055 [n=310] & GSE25065
[n=198]). In the 310-patient cohort the individual TOP2A
and β-tubulin index scores were significantly higher in
responders than non- responders (Figure 4D, p<0.0001
both cases, t-test), the combination of the TOP2A and
β-tubulin indices were associated with increased re-
sponse to treatment (Figure 4E, AUC: 0.76, p < 0.0001),

























β-tubulin signature related to
neoadjuvant response?
C D E
Figure 3 β-tubulin index predicts response to docetaxel chemotherapy. A) Experimental strategy to identify the β-tubulin index. B)
β-tubulin co-expressed probesets within the three discovery cohorts. C) Experimental strategy to validate the β-tubulin index. D) ROC analysis of
β-tubulin index scores and response to docetaxel neoadjuvant chemotherapy (AUC: 0.89, p= 0.002). E) β-tubulin index scores in patients that
experienced pCR or had RD after neoadjuvant chemotherapy (p< 0.0001, t-test).
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(Figure 4F, RD: −0.4, pCR: 1.6, p < 0.0001, t-test). We
made similar observations in the 198-patient cohort,
where individual TOP2A and β-tubulin index scores
were significantly higher in responders than in nonre-
sponders (Figure 4G, p < 0.0001 both cases, t-test), and
the combination index score was associated with
complete pathological response (Figure 4H, AUC: 0.75,
p < 0.0001). Again, combined index scores were higher
in responders than in non-responders (Figure 4I, RD:–
0.3, pCR: 1.3, p < 0.0001, t-test). Taken together these
data reveal the feasibility of combining individual target
indices to predict response to multi-agent chemother-
apy regimens.
TOP2A and β-tubulin indices are more accurate than a
similarly derived proliferation index
Previous work suggests that the prognostic/predictive
power of many breast cancer gene expression signatures
is derived from their capacity to measure proliferation
[2,4,7,32-36]. Hence, it is possible that the TOP2A and
β-tubulin indices described here predict response based
on their capacity to measure proliferation rather than
providing a biologically relevant measurement of target.This is particularly relevant to the TOP2A index, as the
protein product of the TOP2A gene is directly involved
in DNA synthesis. To address this issue we first tested
the capacity of the TOP2A index to predict response in
the docetaxel-only treated cohort. In this fashion, the
capacity of the TOP2A index to predict response to doc-
etaxel would suggest that the predictive capacity of the
TOP2A index is not target specific and may measure a
more general phenomenom related to chemotherapy
sensitivity, such as proliferation. Within this patient co-
hort, the TOP2A index was not significantly associated
with patient response to docetaxel therapy (Figure 5A&B,
AUC: 0.68, p=0.14, RD:–0.26, pCR: 0.65, p=0.12, t-test).
Indeed, these results suggest that the predictive cap-
acity of the TOP2A index is based on measurement of
target rather than proliferation. We also generated a
‘proliferation index’ built using the same methodology
as the TOP2A and β-tubulin indices, around the well
characterized proliferation gene E2F1 [8,37-41]. As
expected, the E2F1 index was related to chemotherapy
response in the 3 large cohorts of breast cancer patients
3 tested previously (GSE21094, GSE25055, GSE25065)
(Additional file 2: Figure S1). Importantly, these results













Figure 4 TOP2A and β-tubulin combination index predicts response to multi-agent anthracycline/taxane chemotherapy. A) Individual
target index scores (A: TOP2A index, T: β-tubulin index) in patients who experienced complete pathological response or had residual disease after
TFAC neoadjuvant chemotherapy (GSE21094, p< 0.0001 both cases, t-test). B) ROC analysis of combination index scores and response to TFAC
neoadjuvant chemotherapy (AUC: 0.78, p< 0.0001). C) Combination index scores in patients who experienced pCR or had RD after neoadjuvant
chemotherapy (p< 0.0001, t-test). D) Individual target index scores of patients who experienced pCR or had RD after AT neoadjuvant
chemotherapy (GSE25055, p< 0.0001 both cases, t-test). E) ROC Analysis of combination index scores and response to AT neoadjuvant
chemotherapy for GSE25055 (AUC: 0.78, p< 0.0001). F) Combination index scores of patients who experienced pCR or had RD after AT
neoadjuvant chemotherapy (p <0.0001, t-test). G) Individual target index scores of patients who experienced pCR or had RD after AT neoadjuvant
chemotherapy (GSE25065, p< 0.0001 both cases, t-test). H) ROC analysis of combination index scores and response to AT neoadjuvant
chemotherapy for GSE25065 (AUC: 0.75, p< 0.0001). I) Combination index scores of patients who experienced complete pathological response or
had residual disease after AT neoadjuvant chemotherapy (p< 0.0001, t-test).




Figure 5 TOP2A and β-tubulin indices are more accurate than a similarly derived proliferation index. A) ROC analusis of TOP2A index and
patient response to neoadjuvant docetaxel therapy (p=0.14). B) TOP2A index scores of patients who experienced pCR or had RD after
neoadjuvant docetaxel chemotherapy (p =0.14, t-test). C) The TOP2A and β-tubulin indices outperform an E2F1-derived proliferation at predicting
response to neoadjuvant chemotherapy in multiple patient datasets (*p <0.05, ANOVA, Tukey’s test).
Q2Table 1 Logistic regression analysis of the GSE25055 &
GSE25065 validation set
Characteristic Odds ratio (95% CI) AUC p-value
Univariate Analyses
AT Index 1.57 (1.39, 1.77) 0.76 <0.001
Age (/10 years) 0.84 (0.68, 1.04) 0.55 0.10
ER Status Positive 0.23 (0.14, 0.37) 0.68 <0.001
Grade 5.28 (2.95, 9.46) 0.69 <0.001
Node Positive 1.16 (0.72, 1.88) 0.52 0.54
Multivariate Analyses
Age (/10 years) 0.89 (0.70, 1.13) 0.78 0.33
ER Status Positive 0.48 (0.27, 0.86) 0.014
Grade 2.24 (1.16, 4.33) 0.016
Node 0.95 (0.54, 1.67) 0.86
AT Index 1.33 (1.14, 1.55) <0.001
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chemotherapy. However, the performance of the E2F1
predictor was inferior to either the TOP2A and β-
tubulin predictors (Figure 5C, *p < 0.05, ANOVA,
Tukeys). Taken together, these data suggest that the
predictive capacity of the TOP2A index is specific to
anthracycline drugs, and moreover, that the TOP2A
and β-tubulin indices are superior to gene signatures
that measure proliferation.
Comparison of the TOP2A and β-tubulin indices with
clinico-pathologic parameters
Reported genomic tests for response to chemotherapy
have generally failed to outperform the predictive cap-
acity of standard clinic-pathological measurements [10].
In this regard we tested whether the TOP2A/β-tubulin
combination index was related to tumor response after
adjusting for standard clinical pathological variables.
Combination of the two previously used data sets
(GSE25055 & GSE25065, 20 patients discarded as pCR/
RD data was unavailable) yielded a data set comprising
488 patients for the analysis. In a univariate analysis that
included estrogen receptor status, tumor grade, nodal
status, patient age, as well as the TOP2A/β-tubulin com-
bination index score, only estrogen receptor status
(AUC: 0.68, p < 0.001), tumor grade (AUC: 0.69,
p < 0.001) and the combination index score (Range
[−5.829, 7.120], AUC: 0.76, p < 0.001) were found to be
statistically significantly related to tumor response,
whereas age and nodal status were not (Table 1). In a
multivariate model (AUC: 0.78), the TOP2A/β-tubulin
combination index score remained statistically signifi-
cantly related to tumor response (p < 0.001) as well as
estrogen receptor status (p= 0.014) and grade (p= 0.016)
(Table 1). In the multivariate model the odds ratio for
the TOP2A/β-tubulin index was 1.33, which indicated
that for each unit increase (i.e. from −3 to −2, from 0 to
1, or from 4 to 5, etc) in the AT index, there was a 1.33times increase in the odds of a patient experiencing
complete pathological response. Importantly, these data
suggest that the TOP2A/β-tubulin combination index
score was related to patient response to chemotherapy
even after adjusting for standard clinical-pathological
variables.
Discussion
Here we describe the identification of TOP2A and β-
tubulin transcript expression indices that predict
complete pathological response to neoadjuvant chemo-
therapy regimens containing anthracycline and taxane
drugs. Complete pathological response represents an ap-
propriate clinical endpoint for these studies as patients
who experience pCR also experience improved survival
compared to those patients who retain RD [13-15]. Not-
ably, TOP2A or β-tubulin, the respective targets of
anthracycline and taxane drugs, have been linked to
anthracycline and taxane response in previous studies,
respectively [17,18,21,42-44]. However, the expression of
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ical predictor of anthracycline or taxane response. We
hypothesized that measurement of target-associated
transcripts in a tumor sample might provide a more com-
prehensive measure of molecular target activity, and thus
the tumor’s likelihood of response to therapy. Indeed,
based on the datasets explored for the studies presented
here, this appears to be the case. Moreover, a combination
index derived from the TOP2A and β-tubulin expression
indices was statistically significantly related to pathological
response in a multivariate model that also included age,
nodal status, tumor grade and estrogen receptor status in
a group of 488 patients treated with anthracycline and tax-
ane based chemotherapy.
From a clinical standpoint, predicting response to
anthracycline and taxane based chemotherapy may be
useful to identify breast cancer patients who have a high
likelihood of benefiting from such regimens. Conversely,
patients predicted to be resistant to anthracycline- and
taxane-based chemotherapy may benefit from enroll-
ment in clinical trials investigating the efficacy of novel
treatments [45]. Many issues remain to be addressed to
confirm the clinical utility of the TOP2A and β-tubulin
indices. In this study our conclusions are based on the
analysis of retrospective data, which limits its clinical
value. Moreover, we did not establish or optimize a
threshold that would serve to separate patients predicted
likely to respond to therapy from those likely to be re-
sistant. Additionally, we did not test the capacity of the
TOP2A index to predict response to neoadjuvant
chemotherapy that consisted of only of an anthracycline,
suggesting that the TOP2A index may be predictive of
general chemotherapy response. Athough we did ob-
serve that the TOP2A index was not predictive of pa-
tient response ot docetaxel. Based on our multivariate
analysis, our data suggests the TOP2A and β-tubulin in-
dices remain predictive even after adjusting for clinical
parameters such as tumor grade and estrogen receptor
status, indicating that these indices likely have clinical
value. Strictly speaking however, a true estimate of the
usefulness of these indices would require a prospective
clinical trial comparing randomly selected with index
selected chemotherapy regimens.
An advantage of the approach taken here is our use of
publicly available data, as well as the efficient use of pa-
tient samples for validation purposes. For example, the
traditional approach for gene signature identification
[2,6,7,9,46], commonly called the top-down approach, mul-
tiple datasets are required that comprise both tumor gene
expression profiles as well as knowledge of the clinical vari-
ables under investigation, for the purposes of signature
identification and subsequent independent validation.
Other approaches, such as large-scale functional based
RNA interference screens, have also yielded predictivesignatures, although these experiments are relatively labour
intensive and expensive [47]. Here, we calculated target in-
dices using datasets for which response to chemotherapy is
not known. In this fashion, we maintained the independ-
ence of datasets for which response to neoadjuvant chemo-
therapy was measured as a clinical variable, thus
maintaining the availability of multiple independent data-
sets for validation.
The identification of gene signatures that predict re-
sponse to chemotherapy also have potential to offer new
insights into the biology of breast tumors, particularly
the transcriptional programs that govern therapy response.
In this regard, it may be possible to identify molecular sig-
naling pathways that either augment chemotherapy resist-
ance or enhance sensitivity. Indeed, the latter strategy
provides a rational approach to identifying new drug regi-
mens, where a signaling pathway inhibitor/activator is
included with the original chemotherapy regimen. In this
fashion, tumors predicted to be therapy resistant might be
rendered sensitive to the original therapy and treatment ef-
ficacy could be increased.
Another important implication of this study is that it
highlights the identification of target based expression
indices as a means to predict response to therapeutics.
For example, it might be possible to generate a target
based expression index for additional molecular targets,
such as the HER2/Neu receptor tyrosine kinase, which is
the molecular target of the humanized monoclonal anti-
body trastuzumab [1] as well as the small molecule
Her2/Neu kinase inhibitor, lapatinib [48,49]. Using such
an approach, therapeutic response to the latter agents
might then be predicted using transcriptional target
based signatures. Indeed, this approach could be tested
for multiple new experimental molecularly targeted
therapies.
Conclusion
Importantly, these findings suggest the practicality of
developing and testing target based indices that predict
response to therapeutics. Moreover, our data highlights
the possibility of using gene signatures to guide the use




All data was publicly available and downloaded from the
gene expression omnibus (http://www.ncbi.nlm.nih.gov/
geo/). Multiple discovery cohorts (GSE2034, GSE7390,
GSE6532) were independently evaluated to determine
target indices for TOP2A, β-tubulin, and E2F1. Together
these cohorts comprised 811 patient tumor gene expres-
sion profiles derived from the Affymetrix U133A micro-
array platform (Table 2). Multiple validation cohorts
Q3
Table 3 Characteristics of the validation cohorts
Characteristic GSE21094 GSE25055 GSE25065 GSE22513
# % # % # % # %
# patients 278 310 198 14
Age, years NA
<=50 133 48 168 54 109 55
>50 144 52 142 46 89 45
NA 1 0
Mean 52 50 49
STD 11 10 11
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ces were related to pathological response to neoadjuvant
chemotherapy (GSE21094 (T/FAC), GSE22513 (T),
GSE25055 & GSE25065 (AT). These cohorts comprised
800 patient tumor gene expression profiles from the
Affymetrix U133A and Affymterix U133 Plus 2.0 micro-
array platforms (Table 2). The clinical characteristics of
the validation cohorts are summarized in Table 3.
The raw intensity files (.CEL) comprising each dataset
were download and normalised using the Robust Multi-
chip Algorithm (RMA)to generate probe set intensities
[50].Nodal status NA NA
Positive 223 72 128 65
Negative 87 28 71 35
NA
Grade NA NA
1 19 6 13 7
2 117 38 63 32
3 151 49 108 55
NA 23 7 14 7
Response
pCR 56 20 58 19 42 21 4 29
RD 222 80 248 80 140 71 10 71
NA 4 1 16 8
ER status NA
Positive 164 49 131 42 123 62
Negative 114 41 174 56 74 37
NA 5 2 1 1
Abbreviations: STD: Standard deviation; pCR: complete pathological response;
RD: Residual disease. ER: Estrogen receptor; NA: Not available.Identification of Target Related Genes
Target index genes were identified by their co-expression
with either TOP2A (TOP2A, 201292_at), β-tubulin
(TUBB, 212320_at), or E2F1 (204947_at) based on a Pear-
son distance function [51]. We filtered these results such
that only probe sets appearing in the most and least 1% of
co- expressed probe sets within each identification cohort
were included in the target index. The final TOP2A index
comprised 86 probe sets with positive and 38 probe sets
with negative correlation to TOP2A transcript levels
(Additional file 1: Table S1). The β-tubulin index com-
prised 28 probe sets with positive and 14 probe sets
with negative correlation to β-tubulin transcript levels
(Additional file 1: Table S2).
To evaluate the target index, the expression values for
each probe set were transformed such that the mean
and standard deviation were set to 0 and 1 in each data-







Where x is the transformed expression, n is the number
of probe sets, P is the set of probes with reported posi-
tive correlation to the target probe set, and N is the set
of probes with reported negative correlation to the target
probe set [46,52].Table 2 Summary of samples used to identify and validate ta
Characteristic Discovery cohorts
GSE2034 GSE7390 GSE6532
Samples 286 198 327
Regimen N/A N/A N/A
Array type U133A U133A U133A
Total arrays: 811
Abbreviations: TFAC: paclitaxel/docetaxel, 5-fluorouracil, doxorubicin, cyclophosphaStatistical Analysis
pCR or RD following treatment with neoadjuvant
chemotherapy was used as the clinical endpoints for this
study. The predictive capacities of the target indices
were evaluated using receiver- operator characteristic
curve (ROC) analysis and both univariate and multivari-
ate logistic regression. T- tests were used to compare in-
dices between responders and non-responders. Welch’s
correction was used when the variance of the index wasrget indices
Validation cohorts
GSE21094 GSE25055 GSE25065 GSE22513
278 310 198 14
TFAC AT AT T
U133 Plus
U133A U133A U133A 2.0
Total arrays: 800
mide; AT: doxorubicin, paclitaxel/docetaxel; T: docetaxel.
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http://www.biomedcentral.com/1755-8794/5/16unequal in these two patient groups. All tests were two-
sided and a p-value of 0.05 or less was considered statis-
tically significant. ANOVA and Tukeys multitple com-
parison test was used to test for differences between
multiple groups (n > 2), and p-values of 0.05 `or less
were considered significant.
Additional files
Additional file 1: Table S1 and Table S2: Elements comprising the
TOP2A and β-tubulin indices. Probe sets comprising the TOP2A and β-
tubulin indices.
Additional file 2: Figure S1: The E2F1 index is predictive of
chemotherapy response in multiple datasets A) GSE21094 (n = 278, TFAC).
B) GSE25055 (n = 310, AT). C) GSE25065(n = 198,AT).
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